恒瑞医药子公司获国家药监局核准签发HRS-2129片的《药物临床试验批准通知书》

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of HRS-2129 tablets, aimed at treating acute and chronic pain, with no similar drugs approved in the domestic market [1] Group 1: Company Developments - Heng Rui Medicine's subsidiary, Shandong Shengdi Pharmaceutical Co., Ltd., and Shanghai Heng Rui Medicine Co., Ltd. have been granted the clinical trial approval for HRS-2129 tablets [1] - The total research and development investment for the HRS-2129 project has reached approximately 112 million yuan [1] Group 2: Industry Context - Currently, there are no approved drugs targeting the same mechanism as HRS-2129 in the domestic market [1]